The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:https://doi.org/10.1176/ajp.100.5.652

1. The majority of schizophrenic patients who improved clinically, showed a significant change in their oral glucose tolerance, this change being towards the normal.

2. In the occasional case, clinical improvement did occur without any significant change in the glucose tolerance.

3. Those who did not improve or deteriorated clinically, showed no change in their abnormal tolerance or it became more abnormal.

4. This change could not be attributed to the administration of insulin per se, nor entirely to the change in absorption of the glucose in the gastro-intestinal tract.

5. The pre-treatment glucose tolerance curves in this series of schizophrenics, seem to show an abnormally prolonged period before the return to fasting levels.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.